FRI0286 Clinical Significance of Serum Matrix Metalloproteinase-3 Normalisation in Rheumatoid Arthritis Patients with Anti-TNF Therapy
Authors: Y. Hattori, A. Kaneko, D. Kida, N. Takahashi, H. Ishikawa, H. Kanda, T. Sato, T. Kojima, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Matrix metalloproteinase-3 (MMP-3) is involved in disruptive events in the cartilage and bone of inflamed joints. In addition, serum MMP-3 is a specific inflammatory marker of the synovium, unlike C-reactive protein (CRP), which is a non-specific inflammatory marker, and is recognized to be correlated with disease activity in patients with rheumatoid arthritis (RA). <h3>Objectives</h3> Our aim in this study was to investigate the relationship between serum MMP-3 and CRP in RA patients treated with Adalimumab (ADA). <h3>Methods</h3> Female RA patients (n=113) in continuation with ADA therapy for 52 weeks in the multicenter study group (Tsurumai Biologics Communication Registry; TBCR, 2176 cases treated with biologics were registered until 2011) were enrolled in this study. All patients were administered 40 mg ADA subcutaneously every 2 weeks. Correlations between serum MMP-3, and CRP levels were analyzed by the Pearson correlation-coefficient. We divided into 3 groups: normal level of CRP ((N, −) group), normal level of CRP and MMP-3 ((N, N) group), and normal level of CRP and abnormal level of MMP-3 ((N, ab-N) group). We evaluated the rate of DAS28-CRP remission (DAS28-CRP &lt;2.3) at 52 weeks in 3 groups. <h3>Results</h3> The serum MMP-3, CRP, and DAS28-CRP levels of all patients at baseline were 268 ng/mL, 2.0 mg/dL, and 5.1, respectively. Serum MMP-3 and CRP levels decreased significantly at 4 weeks (Fig. 1). Significant correlations between serum MMP-3 and CRP levels were found at 0, 4, 12, 24, and 52 weeks (Table). The median DAS28-CRP at 52 weeks in (N, −) group, (N, N) group, and (N, ab-N) group was 2.2, 2.0, and 2.5, respectively. DAS28-CRP at 52 weeks in (N, N) group is significantly lower than in (N, ab-N) group. DAS28-CRP at 52 weeks in (N, −) group is lower than in (N, ab-N) group (Fig. 2). The rate of remission at 52 weeks in (N, −) group, (N, N) group, and (N, ab-N) group was 48%, 58%, and 33%, respectively. The rate of remission at 52 weeks in (N, N) group is significantly higher than in (N, ab-N) group. The rate of remission at 52 weeks in (N, −) group is higher than in (N, ab-N) group (Fig. 3). Normal level of CRP and MMP-3 suggested that high remission rate were preferable at 52 weeks. <h3>Conclusions</h3> In ADA therapy, normal value of serum MMP-3 and CRP can be useful for estimating the DAS28-CRP remission. We considered that serum MMP-3 can be the index of remission in RA patients with anti-TNFα therapy. <h3>Disclosure of Interest</h3> Y. Hattori: None declared, A. Kaneko: None declared, A. Kaneko: None declared, D. Kida: None declared, D. Kida: None declared, N. Takahashi: None declared, N. Takahashi: None declared, H. Ishikawa: None declared, H. Ishikawa: None declared, H. Kanda: None declared, H. Kanda: None declared, T. Sato: None declared, T. Sato: None declared, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1349